Improving Responses to Immunotherapy in Glioblastoma Multiforme

Know about the book -

Improving Responses to Immunotherapy in Glioblastoma Multiforme is written by Stephanie E. B. McArdle and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832548563 (ISBN 10) and 9782832548561 (ISBN 13).

Glioblastoma multiforme (GBM) is a uniformly fatal primary brain tumour. Whilst many therapeutic interventions have been studied pre-clinically very few new therapies have been approved for the use of GBM therapy. These tumours present a unique challenge due to their location within the brain, making delivery of therapeutic interventions challenging. Active immunotherapy represents an attractive avenue for therapy, with activated immune cells being shown to cross the blood brain barrier and penetrate brain tumours. Despite several advances being made in numerous other cancer types, many immunotherapeutic interventions in GBM have failed to make it past phase 3 clinical trials and as of now (2022) no immunotherapeutic interventions have been approved for the therapy of GBM.